Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika...

Zika virus (ZIKV) vaccine development has been hindered by the risk of antibody-dependent enhancement (ADE), particularly in dengue-endemic regions, where sub-neutralizing antibodies can exacerbate disease severity. T cell-based vaccines targeting non-structural (NS) antigens represent a safer alternative that bypasses this risk. Using immunocompetent BALB/c mice, we performed high-resolution in vivo mapping of ZIKV specific CD8⁺ and CD4⁺ T cell responses following ZIKV_PRVABC59 infection, identifying high avidity, polyfunctional memory T cells targeting conserved NS1, NS3 and NS4 proteins. Guided by these data, we developed DNA vaccines encoding full-length NS3 and NS4 and evaluated their efficacy against ZIKV infection alone or combined with a validated construct encoding secreted NS1 (p-tpaNS1). NS3 and NS4 vaccination elicited robust cytotoxic and IFN-γ producing T cell responses, while co-administration with p-tpaNS1 significantly reduced peak serum viremia achieving earlier and stronger viral control. Although NS1 alone conferred strong protection, the multi-antigen formulation demonstrated additive benefits. This T cell-based vaccine approach, targeting conserved NS proteins, offers a scalable, thermostable platform with potential for safe deployment in childbearing women and resource-limited regions. Given NS protein conservation and cross-reactivity across flaviviruses, it also provides a promising foundation for next-generation pan-flavivirus vaccine development, although this remains to be directly tested.